Immunic (STU:10VA) COGS-to-Revenue : 0.00 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Immunic COGS-to-Revenue?

Immunic's Cost of Goods Sold for the three months ended in Mar. 2024 was €0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was €0.00 Mil.

Immunic's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Immunic's Gross Margin % for the three months ended in Mar. 2024 was N/A%.

Immunic COGS-to-Revenue Historical Data

The historical data trend for Immunic's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunic COGS-to-Revenue Chart

Immunic Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

Immunic Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Immunic COGS-to-Revenue Calculation

Immunic's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Immunic's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Immunic (STU:10VA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Immunic's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Immunic COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Immunic's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunic (STU:10VA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (STU:10VA) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

IMUX:USA 10VA:Germany

Address

1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036

Website

https://www.imux.com

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Immunic (STU:10VA) Headlines

No Headlines